1. Home
  2. ACFN vs RNTX Comparison

ACFN vs RNTX Comparison

Compare ACFN & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACFN

Acorn Energy Inc.

SELL

Current Price

$18.39

Market Cap

46.8M

ML Signal

SELL

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.78

Market Cap

47.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACFN
RNTX
Founded
1986
2001
Country
United States
United States
Employees
27
10
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.8M
47.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ACFN
RNTX
Price
$18.39
$1.78
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
12.5K
118.7K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.42
$1.02
52 Week High
$33.00
$2.22

Technical Indicators

Market Signals
Indicator
ACFN
RNTX
Relative Strength Index (RSI) 49.43 68.65
Support Level $18.16 $1.08
Resistance Level $19.87 $2.18
Average True Range (ATR) 0.99 0.19
MACD 0.09 0.04
Stochastic Oscillator 63.27 81.65

Price Performance

Historical Comparison
ACFN
RNTX

About ACFN Acorn Energy Inc.

Acorn Energy Inc is a holding company that focuses on technology-driven solutions for energy infrastructure asset management. The company operates through two segments namely, the PG segment and the CP segment. PG segment provides wireless remote monitoring and control systems and services for critical assets as well as Internet of Things applications which account for the majority of the revenue. CP segment is engaged in providing remote monitoring of cathodic protection systems on gas pipelines for gas utilities and pipeline companies.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: